CHILDREN’S HEALTHCARE OF ATLANTA

Ian’s Friends Foundation Brain Tumor Biorepository at Children’s Healthcare of Atlanta: The biorepository will provide the technology to grow and store cancer cells for use in critical brain tumor research at the Aflac Cancer and Blood Disorders Center of Children’s, and research facilities across the country.

IFF is committed to supporting research that will improve the treatment and outcomes of pediatric brain tumors. After years of supporting research, we found that the lack of available cells for research remains a major impediment to finding cures for childhood tumors. We set out to fund a pediatric tumor biorepository that facilitates sharing cells for research, with the goal of fostering collaboration between medical institutions, universities and hospitals around the world.

Dr. Tobey MacDonald, Pediatric Neuro-Oncology Program Director at Aflac Cancer Center of Children’s Healthcare of Atlanta and with Emory School of Medicine, says “Children’s is an ideal home for this biorepository as we perform more pediatric brain tumor surgeries than almost any other hospital in the nation. Research is a cornerstone of our mission. We seek answers to the most challenging childhood conditions through teaching and research that will help kids worldwide.”

Since it’s formation in 2014, the biorepository has been expanded to include the study of genetic profiles of the cancer stem cells isolated with their corresponding drug sensitivity profile.  As a result of the biorepository, 2 new mutations in the MET oncogene in pediatric glioblastoma have been discovered. Identifying key mutations of the cancer stem cells will allow for tailored treatment plans based on the individual’s genetic “stem-cell profile” of their disease and represents great promise for the treatment of pediatric brain tumors.

Attacking the Cancer Stem Cell to Eradicate Pediatric Brain Tumors: This lab focuses on identifying the genetic profiles of the cancer stem cells isolated with their corresponding drug sensitivity profiles; eventually, patients will be treated in “real-time” based solely on the stringent genetic profile patterns of their cancer stem cells.

Our Research Partnerships

To date, Ian’s Friends Foundation has committed millions of dollars toward pediatric brain tumor research at the cutting-edge research institutions listed below.

Long-term goal is to improve understanding of tumor metabolism to design more effective therapies.
Long-term goal is to improve understanding of tumor metabolism to design more effective therapies.
New biorepository will provide the technology to grow and store cancer cells for use in brain tumor research.
New biorepository will provide the technology to grow and store cancer cells for use in brain tumor research.
Together, these Atlanta institutions pioneer the use of nanotechnology to gauge tumor size, stop tumor growth, and shrink tumors.
Together, these Atlanta institutions pioneer the use of nanotechnology to gauge tumor size, stop tumor growth, and shrink tumors.
Research focused on uncovering the mechanisms by which gene fusions contribute to tumor formation in pediatric low grade gliomas.
Research focused on uncovering the mechanisms by which gene fusions contribute to tumor formation in pediatric low grade gliomas.
Objective is to determine if an electrical stimulations regimen can arrest the division of dividing brain tumor cells.
Objective is to determine if an electrical stimulations regimen can arrest the division of dividing brain tumor cells.
Working to find biomarkers for brain tumors to make the diagnosis of tumor types easier, track their growth or even, no recurrence.
Working to find biomarkers for brain tumors to make the diagnosis of tumor types easier, track their growth or even, no recurrence.
Research establishing the feasibility of using interstitial infusion for treating pediatric brain stem gliomas. FDA approved clinical trial underway.
Research establishing the feasibility of using interstitial infusion for treating pediatric brain stem gliomas. FDA approved clinical trial underway.
Research focused on proteins which are active in pediatric low-grade gliomas. From this research, NYU hopes to better select molecular targeted drugs directed at these pathways.
Research focused on proteins which are active in pediatric low-grade gliomas. From this research, NYU hopes to better select molecular targeted drugs directed at these pathways.
Research focused on using new brain imaging techniques to improve diagnosis, prognosis and treatment of pediatric brain tumors.
Research focused on using new brain imaging techniques to improve diagnosis, prognosis and treatment of pediatric brain tumors.
Partnership between a physician and research scientist is examining innovative drug delivery methods for children with brain tumors.
Partnership between a physician and research scientist is examining innovative drug delivery methods for children with brain tumors.
This groundbreaking project could be the first step for the development of a variety of attractive modalities targeting therapeutic approaches beyond immunotherapy.
This groundbreaking project could be the first step for the development of a variety of attractive modalities targeting therapeutic approaches beyond immunotherapy.
Discovery regarding cancer cells' ability to hijack the brain's nerves could lead to new treatment avenues for aggressive brain tumors.
Discovery regarding cancer cells' ability to hijack the brain's nerves could lead to new treatment avenues for aggressive brain tumors.
Developing a strategy to ensure rapid translation of new drug candidates into clinical trials of medulloblastomas is a collaborative effort.
Developing a strategy to ensure rapid translation of new drug candidates into clinical trials of medulloblastomas is a collaborative effort.
University of Michigan Researchers aim to treat Pediatric Brain Tumors through the combination of Gene and Immune Therapy.
University of Michigan Researchers aim to treat Pediatric Brain Tumors through the combination of Gene and Immune Therapy.
Researchers at Johns Hopkins All Children’s and Johns Hopkins University hypothesize that a group of lncRNAs, including lncRNA HLX2-7, are key molecular signatures (biomarkers) and therapeutic targets for Group III medulloblastoma in children.
Researchers at Johns Hopkins All Children’s and Johns Hopkins University hypothesize that a group of lncRNAs, including lncRNA HLX2-7, are key molecular signatures (biomarkers) and therapeutic targets for Group III medulloblastoma in children.
Scientists work to establish a new system for targeting oncogenic mutations in pediatric brain tumors.
Scientists work to establish a new system for targeting oncogenic mutations in pediatric brain tumors.